» Articles » PMID: 33515275

Lipids, Lysosomes and Mitochondria: Insights into Lewy Body Formation from Rare Monogenic Disorders

Overview
Specialty Neurology
Date 2021 Jan 30
PMID 33515275
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulation of the protein α-synuclein into insoluble intracellular deposits termed Lewy bodies (LBs) is the characteristic neuropathological feature of LB diseases, such as Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with LB (DLB). α-Synuclein aggregation is thought to be a critical pathogenic event in the aetiology of LB disease, based on genetic analyses, fundamental studies using model systems, and the observation of LB pathology in post-mortem tissue. However, some monogenic disorders not traditionally characterised as synucleinopathies, such as lysosomal storage disorders, iron storage disorders and mitochondrial diseases, appear disproportionately vulnerable to the deposition of LBs, perhaps suggesting the process of LB formation may be a result of processes perturbed as a result of these conditions. The present review discusses biological pathways common to monogenic disorders associated with LB formation, identifying catabolic processes, particularly related to lipid homeostasis, autophagy and mitochondrial function, as processes that could contribute to LB formation. These findings are discussed in the context of known mediators of α-synuclein aggregation, highlighting the potential influence of impairments to these processes in the aetiology of LB formation.

Citing Articles

Multi-functional role of apolipoprotein E in neurodegenerative diseases.

Islam S, Noorani A, Sun Y, Michikawa M, Zou K Front Aging Neurosci. 2025; 17:1535280.

PMID: 39944166 PMC: 11813892. DOI: 10.3389/fnagi.2025.1535280.


Molecular Insights into α-Synuclein Fibrillation: A Raman Spectroscopy and Machine Learning Approach.

Coles N, Elsheikh S, Quesnel A, Butler L, Jennings C, Tarzi C ACS Chem Neurosci. 2025; 16(4):687-698.

PMID: 39875340 PMC: 11843597. DOI: 10.1021/acschemneuro.4c00726.


Structural and Functional Characterization of the Most Frequent Pathogenic PRKN Substitution p.R275W.

Bustillos B, Cocker L, Coban M, Weber C, Bredenberg J, Boneski P Cells. 2024; 13(18.

PMID: 39329724 PMC: 11430725. DOI: 10.3390/cells13181540.


Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.

Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z Cell Mol Life Sci. 2024; 81(1):382.

PMID: 39223418 PMC: 11368888. DOI: 10.1007/s00018-024-05419-5.


Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease.

Xu L, Yang Q, Zhou J Int J Mol Sci. 2024; 25(15).

PMID: 39126035 PMC: 11312913. DOI: 10.3390/ijms25158465.


References
1.
Guo Y, Tang B, Guo J . PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes. Front Neurol. 2019; 9:1100. PMC: 6305538. DOI: 10.3389/fneur.2018.01100. View

2.
McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

3.
Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

4.
Babin P, Rao S, Chacko A, Alvina F, Panwala A, Panwala L . Infantile Neuroaxonal Dystrophy: Diagnosis and Possible Treatments. Front Genet. 2019; 9:597. PMC: 6295457. DOI: 10.3389/fgene.2018.00597. View

5.
Hartig M, Iuso A, Haack T, Kmiec T, Jurkiewicz E, Heim K . Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet. 2011; 89(4):543-50. PMC: 3188837. DOI: 10.1016/j.ajhg.2011.09.007. View